Johnson & Johnson (JNJ)
JNJ trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-28, https://www.sec.gov/Archives/edgar/data/200406/000020040626000016/0000200406-26-000016-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-28.
Profile
| Field | Value |
|---|---|
| Ticker | JNJ on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000200406 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | NJ |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $94.2B |
| Net income | $26.8B |
| Operating income | Not in SEC XBRL data |
| Net margin | 28.5% |
| Operating margin | Operating income not reported |
| Revenue growth | +6.0% |
| Cash | $19.7B |
| Total assets | $199.2B |
| P/E (computed) | 25.4× |
| P/S (computed) | 7.2× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-10-21 |
| Cash and burn | $16.9B cash; operating cash flow $6.5B a quarter. | Report 2026-09-27 |
| Shares outstanding | 2,407,310,266 (2026-10-15); 2,409,295,102 a year earlier; 2,407,278,620 three years earlier. | Cover page 2026-10-15 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-02-11 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, Florham Park, New Jersey, United States | PCAOB Form AP 2026-02-26 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $258K, sold $154.9M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-27 | $25.4B | $210.0M | $7.7B | $16.9B | $44.7B | $99.3B | 10-Q 2026-10-21 |
| Q2 2026 2026-06-28 | $25.3B | $5.5B | $8.6B | $20.4B | $49.0B | $97.9B | 10-Q 2026-07-23 |
| Q1 2026 2026-03-29 | $24.1B | $5.2B | $2.5B | $21.7B | $55.0B | $96.4B | 10-Q 2026-04-22 |
| Q4 2025 2025-12-28 | $24.6B | $5.1B | $7.3B | $19.7B | $49.9B | $94.2B | 10-K 2026-02-11 |
| Q3 2025 2025-09-28 | $24.0B | $5.2B | $9.2B | $18.2B | $45.8B | $92.1B | 10-Q 2026-10-21 |
| Q2 2025 2025-06-29 | $23.7B | $5.5B | $3.9B | $18.6B | $50.8B | $90.6B | 10-Q 2026-07-23 |
| Q1 2025 2025-03-30 | $21.9B | $11.0B | $4.2B | $38.5B | $52.3B | $89.3B | 10-Q 2026-04-22 |
| Q4 2024 2024-12-29 | $22.5B | $3.4B | $7.0B | $24.1B | $38.4B | $88.8B | 10-K 2026-02-11 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2026-02-11 |
| Latest annual report | 10-K | 2026-02-11 |
| Latest quarterly / interim | 10-Q | 2026-10-21 |
| Latest current report | 8-K | 2026-10-13 |
| Latest proxy | DEFA14A | 2026-03-11 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +3.5% |
| 1 month | +14.9% |
| 3 months | +9.0% |
| Year to date | +38.1% |
| 1 year | +46.4% |
| From 52-week high | 0.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ABBV | AbbVie Inc. | $294.55 | -0.16% | $520.7B |
| MRK | Merck & Company Inc. Common Stock (new) | $144.46 | -2.23% | $356.1B |
| LLY | Eli Lilly and Company | $1431.67 | -0.82% | $1.35T |
| NVS | Novartis AG | $160.20 | -0.19% | $305.7B |
| AZN | AstraZeneca PLC | $184.02 | -0.23% | $285.4B |
| ABT | Abbott Laboratories | $107.45 | -0.99% | $186.1B |
| NVO | Novo Nordisk A/S | $41.60 | -0.07% | $184.2B |
| PFE | Pfizer Inc. | $28.86 | -0.10% | $164.5B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier